MX2018012459A - Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes. - Google Patents
Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes.Info
- Publication number
- MX2018012459A MX2018012459A MX2018012459A MX2018012459A MX2018012459A MX 2018012459 A MX2018012459 A MX 2018012459A MX 2018012459 A MX2018012459 A MX 2018012459A MX 2018012459 A MX2018012459 A MX 2018012459A MX 2018012459 A MX2018012459 A MX 2018012459A
- Authority
- MX
- Mexico
- Prior art keywords
- dengue virus
- compositions
- den
- methods
- children
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
- C12N2770/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24164—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322167P | 2016-04-13 | 2016-04-13 | |
| PCT/IB2017/052160 WO2017179017A1 (en) | 2016-04-13 | 2017-04-13 | Compositions and methods of vaccination against dengue virus in children and young adults |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018012459A true MX2018012459A (es) | 2019-06-06 |
Family
ID=58671740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012459A MX2018012459A (es) | 2016-04-13 | 2017-04-13 | Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11007261B2 (https=) |
| EP (1) | EP3442571A1 (https=) |
| JP (3) | JP2019511533A (https=) |
| KR (1) | KR102611235B1 (https=) |
| CN (2) | CN109069615B (https=) |
| AU (2) | AU2017250696A1 (https=) |
| BR (1) | BR112018071087A2 (https=) |
| CA (1) | CA3020484A1 (https=) |
| CO (1) | CO2018011355A2 (https=) |
| MX (1) | MX2018012459A (https=) |
| MY (1) | MY192806A (https=) |
| PH (1) | PH12018502175B1 (https=) |
| SG (2) | SG11201808906RA (https=) |
| WO (1) | WO2017179017A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968516B1 (en) | 2013-03-15 | 2022-01-12 | Takeda Vaccines, Inc. | Compositions and methods for dengue virus chimeric constructs in vaccines |
| JP2019511533A (ja) * | 2016-04-13 | 2019-04-25 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 |
| TW202309276A (zh) | 2016-08-03 | 2023-03-01 | 美商武田疫苗股份有限公司 | 用於與經改良之調配物一起穩定黃病毒的組成物及方法 |
| WO2019112921A1 (en) * | 2017-12-07 | 2019-06-13 | Merck Sharp & Dohme Corp. | Formulations of dengue virus vaccine compositions |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| EP3846849A1 (en) * | 2018-09-05 | 2021-07-14 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| BR112022001476A2 (pt) * | 2019-08-16 | 2023-10-03 | Takeda Vaccines Inc | Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit |
| BR112022015710A2 (pt) | 2020-02-27 | 2022-09-27 | Takeda Vaccines Inc | Método para remover dna de célula hospedeira a partir da preparação de vírus |
| EP3892737A1 (en) * | 2020-04-09 | 2021-10-13 | Takeda Vaccines, Inc. | Qualitative and quantitative determination of single virus haplotypes in complex samples |
| WO2023147342A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| US20250177511A1 (en) | 2022-02-15 | 2025-06-05 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| US20250342705A1 (en) | 2022-05-04 | 2025-11-06 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| EP4605562A1 (en) * | 2022-10-20 | 2025-08-27 | Takeda Vaccines, Inc. | A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype |
| EP4612495A1 (en) * | 2022-11-02 | 2025-09-10 | Takeda Vaccines, Inc. | A method for determining the infectivity of a virus |
| WO2024108087A1 (en) | 2022-11-18 | 2024-05-23 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
| EP4626574A1 (en) | 2022-11-29 | 2025-10-08 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE481982T1 (de) * | 2002-05-03 | 2010-10-15 | Us Gov Health & Human Serv | Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2. |
| US8968996B2 (en) * | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| AU2010256845B2 (en) | 2009-06-01 | 2016-09-22 | Takeda Vaccines, Inc. | Compositions and methods for administration of vaccines against dengue virus |
| SG11201401733VA (en) * | 2011-10-25 | 2014-09-26 | Florida Gulf Coast University | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes |
| JP2015520196A (ja) * | 2012-06-10 | 2015-07-16 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | デングウイルスに対するワクチン投与のための組成物および方法 |
| SG10201912291YA (en) | 2012-07-24 | 2020-02-27 | Sanofi Pasteur | Vaccine compositions |
| TW201428101A (zh) * | 2012-11-08 | 2014-07-16 | Inviragen Inc | 登革熱病毒血清型４型之建構物的組成物、方法及用途 |
| US9878031B2 (en) | 2012-12-14 | 2018-01-30 | Takeda Vaccines, Inc. | Compositions, methods of administration and uses for trivalent dengue virus formulations |
| EP2968516B1 (en) * | 2013-03-15 | 2022-01-12 | Takeda Vaccines, Inc. | Compositions and methods for dengue virus chimeric constructs in vaccines |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| JP2019511533A (ja) * | 2016-04-13 | 2019-04-25 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 |
| EP3846849A1 (en) * | 2018-09-05 | 2021-07-14 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| US11464815B2 (en) * | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
-
2017
- 2017-04-13 JP JP2018553428A patent/JP2019511533A/ja active Pending
- 2017-04-13 US US16/093,385 patent/US11007261B2/en active Active
- 2017-04-13 WO PCT/IB2017/052160 patent/WO2017179017A1/en not_active Ceased
- 2017-04-13 CN CN201780028507.XA patent/CN109069615B/zh active Active
- 2017-04-13 CA CA3020484A patent/CA3020484A1/en active Pending
- 2017-04-13 CN CN202510170711.1A patent/CN120392993A/zh active Pending
- 2017-04-13 AU AU2017250696A patent/AU2017250696A1/en not_active Abandoned
- 2017-04-13 SG SG11201808906RA patent/SG11201808906RA/en unknown
- 2017-04-13 BR BR112018071087-3A patent/BR112018071087A2/pt active Search and Examination
- 2017-04-13 MY MYPI2018001735A patent/MY192806A/en unknown
- 2017-04-13 SG SG10201913383RA patent/SG10201913383RA/en unknown
- 2017-04-13 PH PH1/2018/502175A patent/PH12018502175B1/en unknown
- 2017-04-13 KR KR1020187032733A patent/KR102611235B1/ko active Active
- 2017-04-13 EP EP17721858.3A patent/EP3442571A1/en active Pending
- 2017-04-13 MX MX2018012459A patent/MX2018012459A/es unknown
-
2018
- 2018-10-24 CO CONC2018/0011355A patent/CO2018011355A2/es unknown
- 2018-11-19 AU AU2018267542A patent/AU2018267542B2/en active Active
-
2021
- 2021-04-13 US US17/229,109 patent/US20210236620A1/en not_active Abandoned
-
2022
- 2022-04-20 JP JP2022069423A patent/JP2022089964A/ja active Pending
-
2024
- 2024-03-21 JP JP2024044760A patent/JP2024071463A/ja not_active Withdrawn
- 2024-08-30 US US18/821,030 patent/US20250235522A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201808906RA (en) | 2018-11-29 |
| PH12018502175B1 (en) | 2023-12-06 |
| AU2018267542B2 (en) | 2020-06-18 |
| WO2017179017A1 (en) | 2017-10-19 |
| CO2018011355A2 (es) | 2018-11-13 |
| US11007261B2 (en) | 2021-05-18 |
| AU2017250696A1 (en) | 2018-11-22 |
| JP2019511533A (ja) | 2019-04-25 |
| KR102611235B1 (ko) | 2023-12-08 |
| US20250235522A1 (en) | 2025-07-24 |
| JP2022089964A (ja) | 2022-06-16 |
| JP2024071463A (ja) | 2024-05-24 |
| BR112018071087A2 (pt) | 2019-02-26 |
| SG10201913383RA (en) | 2020-03-30 |
| AU2018267542A1 (en) | 2018-12-13 |
| CA3020484A1 (en) | 2017-10-19 |
| US20190381163A1 (en) | 2019-12-19 |
| CN120392993A (zh) | 2025-08-01 |
| MY192806A (en) | 2022-09-09 |
| CN109069615B (zh) | 2025-03-04 |
| KR20180137514A (ko) | 2018-12-27 |
| EP3442571A1 (en) | 2019-02-20 |
| US20210236620A1 (en) | 2021-08-05 |
| CN109069615A (zh) | 2018-12-21 |
| PH12018502175A1 (en) | 2019-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018011355A2 (es) | Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes | |
| AR093421A1 (es) | Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4 | |
| MX2015012893A (es) | Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas. | |
| Angenvoort et al. | West Nile viral infection of equids | |
| Khetarpal et al. | Dengue fever: causes, complications, and vaccine strategies | |
| PE20140646A1 (es) | Vacuna de virus de dengue inactivado | |
| Huang et al. | Vaccine development for mosquito-borne viral diseases | |
| JP2016513970A5 (https=) | ||
| MX2018010958A (es) | Vacuna para virus de zika atenuado vivo. | |
| BR112018077540A2 (pt) | vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado | |
| CO6470882A2 (es) | Composiciones y metodos para administración de vacunas contra virus del dengue. | |
| JP2016504315A5 (https=) | ||
| BR112016002354A2 (pt) | composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit | |
| JP2019511221A5 (https=) | ||
| CO2021017772A2 (es) | Virus del dengue atenuados | |
| PH12021550785A1 (en) | Virus vaccine | |
| BR112016029201A2 (pt) | vírus do oeste do nilo/dengue quiméricos e métodos de uso | |
| Wei et al. | Recent progress in dengue vaccine development | |
| BR0010969A (pt) | Vacina polivalente antivìrus da dengue | |
| Stovba et al. | Using the vaccinia virus MVA strain for developing recombinant vector vaccines against current arboviral infections | |
| TH170668A (th) | องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน | |
| AR094238A1 (es) | Composicion vacunal contra el virus dengue |